Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Allogene Therapeutics ( (ALLO) ) is now available.
On June 18, 2025, Allogene Therapeutics held its Annual Meeting of Stockholders, where key decisions were made. Stockholders elected three Class I Directors to serve until 2028, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent accounting firm for 2025.
The most recent analyst rating on (ALLO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.
Spark’s Take on ALLO Stock
According to Spark, TipRanks’ AI Analyst, ALLO is a Neutral.
Allogene Therapeutics is facing substantial financial challenges with persistent losses and reliance on external funding, which significantly impacts its stock score. The technical analysis indicates bearish momentum, and valuation metrics show a lack of profitability. Despite some positive developments from the earnings call regarding clinical trials and cash management, these are not enough to offset the broader financial and operational hurdles.
To see Spark’s full report on ALLO stock, click here.
More about Allogene Therapeutics
Allogene Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of allogeneic CAR T cell therapies for cancer treatment.
Average Trading Volume: 3,084,606
Technical Sentiment Signal: Sell
Current Market Cap: $269M
For a thorough assessment of ALLO stock, go to TipRanks’ Stock Analysis page.